Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research & Development In Brief

This article was originally published in The Tan Sheet

Executive Summary

Omega-6 lowers heart disease risk: The American Heart Association recommends consuming 5 percent to 10 percent of energy from omega-6 polyunsaturated fatty acids to lower the risk of coronary heart disease. The association released the science advisory Jan. 27 in response to studies suggesting "some individuals" should reduce omega-6 consumption despite a "large body of literature" that says higher intake reduces CHD. Research against increased consumption says omega-6 contributes to vascular inflammation and luminal narrowing in women with CHD. Other research that tips the scale in favor of omega-6 consumption suggests it lowers low-density lipoprotein cholesterol, which can inflame vascular tissue. Omega-6 also may improve insulin resistance to reduce diabetes mellitus, lower blood pressure and reduce stroke risk. It is not associated with cancer, according to the advisory and research review

You may also be interested in...



Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC

In Brief

Combe sells most of its OTC brands

People In Brief

Perrigo promotes in pricing, planning

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102666

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel